Ascendis Pharma A/S ASND 深 沪
等待开盘 09-01 09:30:00 美东时间
263.04
+15.130
+6.10%
华盛通- 最 高268.98
- 今 开247.65
- 成交量 102.62万股
- 最 低 247.65
- 昨 收 247.91
- 总市值 172.54亿
- 52周最高 282.15
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 186.054
- 委 比 -41.16%
- 总股本 6559.28万
- 历史最高 282.15
- 量 比 3.65
- 振 幅 8.60%
- 历史最低 11.92
- 每 手 1
- 风险率 20.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
今天 08:37
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injectio...
08-31 20:06
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market capitalization of $16.63 billion. Buying $1000 In ASND: If an investor had bought $1000 of ASND stoc...
08-26 22:45
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
08-19 18:07
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), Quantum-Si (QSI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-14 22:20
Ascendis Pharma A/S reports Q2 results
Ascendis Pharma A/S press release (ASND): Q2 Revenue of €339M. Research and development expenses for the second quarter of 2026 were €76 million, compared to €72 million during the same period in 2025...
08-14 03:10
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market capitalization of $16.84 billion. Buying $100 In ASND: If an investor had bought $100 of ASND stock 5 ...
08-11 22:15
